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Platelet-VWF complexes are preferred substrates ofADAMTS13 under ﬂuid
shear stress
Kyuhwan Shim,1 Patricia J.Anderson,1 ElodeeA. Tuley,1 Erin Wiswall,2 and J. Evan Sadler1
1Departments of Medicine and Biochemistry and Molecular Biophysics, and Howard Hughes Medical Institute, Washington University School of Medicine,S t
Louis, MO; and 2Wyeth Biotech,Andover, MA
Endothelial cells secrete prothrombotic ul-
tralargevonWillebrandfactor(VWF)multim-
ers, and the metalloprotease ADAMTS13
cleaves them into smaller, less dangerous
multimers. This reaction is stimulated by
tensile force applied to the VWF substrate,
which may occur on cell surfaces or in the
circulating blood. The cleavage of soluble
VWF by ADAMTS13 was accelerated dra-
matically by a combination of platelets and
ﬂuid shear stress applied in a cone-plate
viscometer. Platelet-dependent cleavage of
VWF was blocked by an anti-GPIb mono-
clonal antibody or by a recombinant soluble
fragment of GPIb that prevents platelet-
VWF binding. Multimeric gel analysis
showed that shear and platelet-dependent
cleavage consumed large VWF multimers.
Therefore,ADAMTS13 preferentially acts on
platelet-VWF complexes under ﬂuid shear
stress.Thisreactionislikelytoaccountfora
majority of VWF proteolysis after secretion
andtodeterminethesteady-statesizedistri-
bution of circulating VWF multimers in vivo.
(Blood. 2008;111:651-657)
© 2008 by TheAmerican Society of Hematology
Introduction
von Willebrand factor (VWF) is a multimeric plasma glycoprotein
that plays an essential role in tethering platelets at the site of
vascular injury. VWF is synthesized in endothelial cells, where a
portion is stored in granules called Weibel-Palade bodies as
“unusually large” or “ultralarge” multimers (ULVWF) and secreted
upon endothelial stimulation.1,2 Secreted ULVWF multimers bind
platelets with relatively high afﬁnity and are thought to be
prothrombotic. ULVWF is cleaved into smaller and less dangerous
multimers by the metalloprotease ADAMTS13, a member of the
A Disintegrin And Metalloprotease with ThromboSpondin type I
repeat family.3-5 Inherited or acquired deﬁciency of ADAMTS13
causes life-threatening microvascular thrombosis that is character-
istic of thrombotic thrombocytopenic purpura.4,6,7 Conversely,
mutations in von Willebrand disease type 2A cause bleeding by
increasing the cleavage of VWF by ADAMTS13 and impairing
platelet adhesion.8-10 Therefore, normal hemostasis depends on the
precise regulation of VWF proteolysis.
ADAMTS13 cleaves the Tyr1605-Met1606 bond in theA2 domain
of VWF, but this bond is buried and relatively inaccessible until the
A2 domain is unfolded, presumably by tensile force in vivo.10,11
The shear stress required to apply this force will vary depending on
whether VWF is immobilized at the vessel wall or moving with the
ﬂowing blood, and whether platelets are bound to it. The rate of
VWF cleavage also can be modulated by cofactors that bind to the
A1 domain, including platelet GPIb and heparin.12 Thus,
ADAMTS13 is presented with VWF multimers in plasma or on
endothelial cell surfaces that vary in their susceptibility to cleav-
age, with or without attached platelets.
The relevance of each of these potential substrates to the
catabolism of VWF is unknown. Several studies suggest that VWF
strings on endothelial cells must be cleaved to inhibit thrombus
growth,13,14 but the role of proteolysis in the ﬂuid phase has not
been established. Therefore, the cleavage of VWF byADAMTS13
was assessed in a cone-plate viscometer to minimize the contribu-
tion of surface interactions. The results indicate that proteolysis of
ﬂuid phase VWF-platelet complexes is likely to determine the
steady state size distribution of circulatingVWF multimers in vivo.
Methods
Recombinant ADAMTS13
Full-length humanADAMTS13 with a C-terminal V5 tag was expressed in
TRex 293 cells (Invitrogen) as described previously15 and partially puriﬁed
by anion exchange chromatography. In brief, conditioned medium contain-
ing recombinantADAMTS13 was supplemented with proteinase inhibitors
(0.1 mol/L D-Phe-Pro-Arg-chloromethane and 144 mol/Lphenylmethyl-
sulfonyl ﬂuoride and applied to tandem columns of HiTrap Q Sepharose
(2  5 mL; GE Healthcare, Chalfont St Giles, United Kingdom). The
columns were washed with 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, and
developed with a linear gradient of 0 to 50 mM CaCl2 in 20 mM Tris-HCl,
pH 8.0, and 100 mM NaCl. Fractions containing ADAMTS13 were
combined, dialyzed against 20 mM Tris-HCl, pH 8.0, and 100 mM NaCl,
and concentrated by ultraﬁltration (YM100; Millipore, Billerica, MA).
Protein concentration was determined by bicinchoninic acid assay (Pierce,
Rockford, IL). ADAMTS13 antigen concentration was determined with an
IMUBINDADAMTS13 enzyme-linked immunosorbent assay (ELISA) Kit
(American Diagnostica, Greenwich, CT), and by ELISA using monoclonal
anti-human ADAMTS13 antibody 2G3 provided by Hans Deckmyn
(Catholic University of Leuven, Leuven, Belgium)16 for coating and
horseradish peroxidase-conjugated anti-V5 antibody (Invitrogen, Carlsbad,
CA) for detection.ADAMTS13 activity was assayed based on the cleavage
of substrate FRETS-VWF73 (Peptides International, Louisville, KY).17The
recombinant ADAMTS13 stock solution contained approximately
250 units/mL, whereas the concentration of active ADAMTS13 in normal
pooled plasma is deﬁned as 1 unit/mL.
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Lyophilized formalin-ﬁxed human platelets (Helena Laboratories, Beau-
mont, TX) were reconstituted in 20 mM Tris-HCl, pH 7.4, and 100 mM
NaCl and centrifuged at 6400g for 5 minutes.The pellet was resuspended in
the same buffer to a platelet concentration of 2  107/L as determined by
counting in a phase hemacytometer.
Washed fresh human platelets were prepared as described previously18
from blood anticoagulated with 4.4 mM K2-ethylenediaminetetraacetic acid
(K2EDTA) and 10 ng/mL prostaglandin I2 (Cayman Chemical, Ann Arbor,
MI).19The washed platelets were gently resuspended in platelet wash buffer
(6.6 g/L NaCl, 1 g/L dextrose, 0.747 g/L K2HPO4, 1.15 g/L Na2HPO4 
7H2O, 3.37 g/L NaH2PO4  H2O, plus 10 ng/mL prostaglandin I2)t oa
concentration of 2  107/Land used within 24 hours.
Platelet-rich plasma was prepared from freshly drawn venous blood
anticoagulated with 14.4 U/mL heparin, 10 ng/mL prostaglandin I2, and
10 mol/L D-Phe-Pro-Arg-chloromethane by centrifugation at 480g for
10 minutes. The platelet-rich plasma supernatant was centrifuged at 6400g
for 5 minutes to prepare platelet-poor plasma.
Shear-induced proteolytic cleavage of VWF
Reactions were performed in a programmable cone-plate viscometer
(HAAKE RheoStress 1; Thermo Fisher Scientiﬁc, Waltham, MA) in a total
volume of 50 L(with a 20-mm diameter cone, 0.5° cone angle) or 500 L
(with a 60-mm diameter cone, 0.5° cone angle) of reaction buffer (50 mM
HEPES, pH 7.4, 150 mM NaCl, 144 mol/L phenylmethylsulfonyl
ﬂuoride, 10 mol/L D-Phe-Pro-Arg-chloromethane, 0.1 mol/L ZnCl2,
5 mM CaCl2, and 3 mg/mL bovine serum albumin [BSA]), with various
amounts of puriﬁed plasma VWF (Haematologic Technologies, Essex
Junction,VT), platelets,ADAMTS13, and other components as indicated in
the article or ﬁgure legends. Complete reaction mixtures were preincubated
at 37°C for 10 minutes and then subjected to a constant ﬂuid shear stress for
various times. In some experiments, platelets were preincubated for
30 minutes with 30 g/mL of monoclonal anti-human GPIb antibody
6D120 provided by Dr Barry Coller (Rockefeller University, New York,
NY), a recombinant chimeric protein consisting of human GPIb residues
1-290 fused to the Fc region of human IgG1 (GPIb-Ig/2V),21 or mouse
IgG1 (BioLegend, San Diego, CA). Reactions were stopped by mixing
15-L samples with an equal volume of Laemmli sample buffer (Bio-Rad
Laboratories, Hercules, CA). Platelets were obtained for these studies under
a protocol approved by the Washington University institutional review
board. Informed consent was obtained in accordance with the Declaration
of Helsinki.
A standard cleavage product was prepared in a 500-L reaction
containing 2  106 platelets/L, 30 g/mL VWF, and 5 U/mL
ADAMTS13. The mixture was subjected to 50 dyne/cm2 shear stress for
30 minutes, mixed with 500 L of Laemmli sample buffer, and stored in
aliquots of 20 La t70°C. For use, an aliquot was mixed with 180 Lo f
Laemmli sample buffer containing 3 mg/mL BSAand processed in parallel
with experimental reactions. A sample of the diluted standard solution
(7.5 L) was analyzed by SDS-polyacrylamide gel electrophoresis (PAGE)
in a reference lane for each gel.
Western blotting
Reaction products in Laemmli sample buffer were heated at 90°C for
5minuteswithoccasionalvortexingandcentrifugedat6400gfor5minutes.
The supernatants were subjected to 4% SDS-PAGE and transferred to
polyvinylidene diﬂuoride (PVDF) membranes (Invitrogen). The mem-
branes were incubated (1 hour at room temperature, or overnight at 4°C) in
20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% Tween 20 (TBST)
containing 0.5% casein, and then incubated (1 hour at room temperature, or
overnight at 4°C) with a 1:2500 dilution of horseradish peroxidase-
conjugated rabbit anti-VWF antibody (P0226, Dako, Carpinteria, CA) in
TBST. Membranes were washed twice for 15 minutes in TBST and
developed with the ECL plus Western blotting detection system (GE
Healthcare, NJ).
Image analysis
Membranes were exposed directly to ﬁlm and scanned ﬁlms were analyzed
using NIH ImageJ (rsb.inf.nih.gov/ij). Membranes also were scanned with a
Storm or Typhoon scanner (GE Healthcare) for chemiﬂuorescence detec-
tion and analysis using ImageQuant software (version 5.1 or TL, GE
Healthcare). The intensities of homodimeric 350-kDA product bands7,11
were normalized to the intensity of the standard cleavage product, which
was included on each gel.
Multimer gels
Samples were removed from reactions and mixed with an equal volume of
50 mM EDTA. VWF multimers were analyzed as described previously22 by
1.5% SDS-agarose gel electrophoresis and transfer to PVDF membranes.
Multimers were visualized with horseradish peroxidase-conjugated rabbit anti-
VWF antibody and the ECLchemiluminescence system (GE Healthcare).
Results
VWF multimers encounter many distinct environments that are
likely to differ in their importance for the proteolytic remodeling of
VWF by ADAMTS13. Upon secretion by endothelial cells, VWF
multimers can remain bound to the cell surface or detach and
circulate in the blood. Cell-associated VWF binds platelets with
high afﬁnity and is cleaved rapidly byADAMTS13, suggesting that
cell surfaces are an important site for VWF proteolysis.13Although
VWF multimers in the blood are relatively resistant toADAMTS13
under static conditions they are cleaved readily at high levels of
ﬂuid shear stress that occur in the microvasculature,23 suggesting
that ﬂuid phase cleavage ofVWF also may be signiﬁcant in vivo. In
addition, shear stress promotes VWF-dependent platelet aggrega-
tion,24 which could inﬂuence the recognition of VWF by
ADAMTS13. Therefore, the dependence of VWF cleavage in
solution on shear stress and platelet count was investigated in a
cone-plate viscometer, to minimize the contribution of wall shear
stress and focus on ﬂuid phase interactions between VWF and
platelets.VWF cleavage byADAMTS13 was assessed as described
previously,7,11 using SDS-PAGE and Western blotting to detect a
homodimeric 350 kDa product composed of C-terminal fragments
of the VWF subunit.
VWF was cleaved very slowly by ADAMTS13 under static
conditions in the absence of platelets (Figure 1A lane 3). Cleavage
was increased approximately 2-fold by adding platelets (Figure 1A
lane 4), which is consistent with the previously described stimula-
tion ofADAMTS13 activity upon binding of a high afﬁnity variant
of GPIb to recombinant VWF substrates12 even though relatively
littleVWF-plateletbindingoccursintheabsenceofshearstress.25-27
Fluid shear stress alone increased the cleavage of VWF approxi-
mately 3-fold (Figure 1Alane 7), whereas the combination of shear
stress and platelets increased the cleavage of VWF approximately
12-fold (Figure 1A lane 8). As expected, the addition of EDTA
prevented cleavage (Figure 1A lane 9). Thus, platelet-VWF
complexes subjected to shear stress appear to be good substrates for
ADAMTS13.
The role of direct VWF-platelet interactions was demonstrated
by 2 approaches. Monoclonal anti-GPIb antibody 6D1 prevents
the binding of VWF to platelet GPIb,20 and pretreatment of
platelets with antibody 6D1 also blocked the shear stress-induced
cleavage of VWF (Figure 1B lane 8 vs lane 7). Antibody 6D1 had
no effect on shear stress-induced cleavage of VWF when platelets
were omitted (Figure 1B lane 4 vs lane 3).
Similar results were obtained using a recombinant fragment of
GPIb fused to the Fc region of human IgG1 (GPIb-Ig/2V).21
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pseudo-von Willebrand disease, G233V and M239V.28,29 These
mutations increase the afﬁnity of binding to VWF, and GPIb-
Ig/2V binds immobilized VWF with an IC50 of 0.5 g/mL.21At the
concentrations of VWF and GPIb-Ig/2V used in these experi-
ments (30 g/mL each), almost all GPIb-Ig/2V binding sites on
VWF will be occupied. In the absence of platelets, GPIb-Ig/2V
substantially increased the cleavage of VWF (Figure 1C lane 4 vs
lane 2), probably by binding toVWF domainA1 and enhancing the
recognition of the adjacentA2 domain byADAMTS13 as reported
for a similar construct.12 The addition of platelets markedly
increased the cleavage ofVWF (Figure 1C lane 6) and this increase
was partially inhibited by GPIb-Ig/2V (Figure 1C lane 8). These
results suggest that GPIb-Ig/2V is both a cofactor for AD-
AMTS13 because it binds VWF domainA1,12 and an antagonist of
shear-induced VWF cleavage because it inhibits VWF binding to
platelets.21
These results demonstrate that platelets increase the shear-
dependent cleavage of VWF by ADAMTS13 using puriﬁed
proteins. To establish that a similar effect occurs under more
physiologic conditions, similar studies were performed in platelet-
rich and platelet-poor plasma anticoagulated with heparin, prosta-
cyclin and D-Phe-Pro-Arg-chloromethane (Figure 1D). Under these
conditions, a normal platelet count markedly increased the shear-
dependent cleavage of endogenous plasma VWF by endogenous
ADAMTS13.
Platelet-dependent cleavage of VWF depended strongly on the
level of ﬂuid shear stress (Figure 2A) and exhibited a maximum
between 10 and 30 dyne/cm2. In the absence of platelets, the extent
of VWF cleavage varied much less as a function of shear stress.
With both platelets and shear stress, the extent of VWF cleavage
increased approximately linearly with time (Figure 2B), indicating
that ADAMTS13 activity was stable during the time course of the
experiments. Compared with the very slow rate of product forma-
tion without platelets or shear stress, the addition of platelets or
exposure to ﬂuid shear stress modestly increased the cleavage of
VWF. The extent of VWF cleavage also was proportional to
ADAMTS13 concentration (Figure 2C).
The cleavage of VWF increased markedly with increasing
platelet count (Figure 3). Similar results were obtained with
formalin ﬁxed platelets and with fresh washed platelets treated with
EDTA and prostacyclin to prevent activation and aggregation.
Because of the intrinsic variability of the Western blotting assay
method,manyreplicateswererequiredtoobtainsatisfactoryresults
at low signal intensities associated with lower platelet counts. The
results shown represent the average of 9 independent experiments.
The maximumVWF cleavage induced at the highest platelet counts
varied several-fold among the replicates, which accounts for the
relatively large standard errors on the data points at higher platelet
counts. A steep increase in VWF cleavage by ADAMTS13 was
observed over a physiologically relevant range of platelet counts,
between 125 000/L and 500 000/L, with little effect at lower
counts. This sigmoidal pattern can be ﬁt to a standard binding
equation with a Hill coefﬁcient of approximately 2, suggesting that
optimal cleavage requires at least 2 platelets to bind simultaneously
to a single VWF multimer.
ULVWF multimers bind to platelets more tightly than smaller
multimers.30 In addition, the likelihood that a multimer will bind
several platelets should increase with multimer length, which
correlates with the number of potential platelet binding sites.
Therefore, platelets may bind to and promote the cleavage of larger
multimers, and the results of multimer gel electrophoresis are
consistent with this expectation (Figure 4). When plasma VWF
multimers were exposed to ﬂuid shear stress, no change in multimer
distribution was observed if either platelets or ADAMTS13 was
omitted. A recent study described an increase in VWF multimer size
upon exposure of concentrated VWF (0.1 mg/mL) to approximately
65 dyne/cm2 shear stress.31 In the present studies, this effect may have
been prevented by the use of a lower VWF concentration (30 g/mL),
lower shear stress (16 dyne/cm2), and the presence of BSA(3 mg/mL).
When both ADAMTS13 and platelets were included, larger VWF
multimers disappeared and smaller multimers increased. So-called
satellite bands ﬂanking the smaller multimers are caused by proteolysis,
and these bands increased markedly when VWF was subjected to shear
stress with both platelets andADAMTS13 present.
Figure 1. Fluid shear stress and platelet-VWF interactions increase VWF
cleavage by ADAMTS13. Reactions containing VWF (30 g/mL) were treated with
() or without () shear stress and other components as indicated. Samples were
analyzed by SDS-PAGE and Western blotting with polyclonal anti-VWF to detect the
350-kDa homodimeric cleavage product containing C-terminal fragments of VWF.
The corresponding 280-kDa N-terminal homodimeric product is recognized less
efﬁciently by anti-VWF and was visible in some reactions. (A) Cleavage of VWF by
ADAMTS13 (5 U/mL) was increased slightly by ﬂuid shear stress (50 dyne/cm2 for
10 minutes, lane 7) or formalin-ﬁxed platelets (106/L, lane 4). Maximal cleavage
required both shear stress and platelets (lane 8) and was blocked by 5 mM EDTA
(lane 9). (B) Monoclonal antibody 6D1 against GPIb (30 g/mL) blocked the
cleavage of VWF exposed to ﬂuid shear stress (50 dyne/cm2 for 10 minutes) in
reactions containing platelets (lane 8) but not in reactions without platelets (lane 4).
Control mouse IgG1 had no effect (lanes 3 and 7). (C) Recombinant GPIb-Ig/2V
(30 g/mL) increased the cleavage of VWF by ADAMTS13 (2.5 U/mL) in reactions
exposed to ﬂuid shear stress (16 dyne/cm2 for 5 minutes) without platelets (lane 4)
and partially inhibited the cleavage of VWF in reactions with platelets (lane 8). (D)The
cleavage of endogenous VWF in fresh platelet-rich plasma subjected to ﬂuid shear
stress (20 dyne/cm2 for 5 minutes) was markedly greater than the cleavage of VWF in
platelet-poor plasma. Cleavage was prevented by 50 mM EDTA.
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demonstrated directly by analyzing the VWF eluted from platelets
after exposure to ﬂuid shear stress (Figure 5). No VWF was
detected in reactions containing only formalin-ﬁxed platelets,
indicating that little or no VWF can be extracted from them. When
plasma VWF was included, a small amount of VWF was sedi-
mented in reactions that were subjected to shear stress in the
absence of platelets (Figure 5 lane 2). In reactions prepared with
platelets but not subjected to shear stress (Figure 5 lane 3), trace
amounts of relatively small VWF multimers sedimented with the
platelets. In contrast, combining shear stress with platelets mark-
edly increased the recovery of largerVWF multimers in the platelet
pellet (Figure 5 lane 4). Comparison with a VWF standard on the
same gel suggests that ﬂuid shear stress caused approximately 5%
to 10% of the input VWF to bind to platelets. Thus, ﬂuid shear
stress induces the binding of large VWF multimers to platelets, and
platelet-VWF complexes appear to be preferred substrates for
ADAMTS13.
Discussion
In the absence of ﬂuid shear stress, VWF binds very weakly
to platelet GPIb with a Kd o f3t o5mol/L.25-27 Therefore,
Figure 2. VWF cleavage depends on shear stress, time, platelets, and AD-
AMTS13. (A) Reactions containing VWF (30 g/mL) and ADAMTS13 (2.5 U/mL),
without platelets () or with platelets (1  106/L) (f), were subjected to different
levels of ﬂuid shear stress for 3 minutes and analyzed for VWF cleavage by
SDS-PAGE and Western blotting with polyclonal anti-VWF. Error bars indicate SD
(n  5, f) or the range of duplicates (). (B) Reactions containing VWF (30 g/mL)
and ADAMTS13 (2.5 U/mL), without (F, E) or with formalin-ﬁxed platelets (106/L)
(f, ) were performed without (, E) or with (f, F) 50 dyne/cm2 shear stress for
different times and analyzed for VWF cleavage. f, 50 dyne/cm2 shear stress and 106
platelets/L(n 5); F, 50 dyne/cm2 and no platelets (n  2); , no shear stress and
106 platelets/L( n 2); E, no shear stress and no platelets (n  1). Error bars
indicate SD (f) or the range of duplicates (F, E). (C) Reactions containing the
indicated concentration ofADAMTS13 (U/mL) with or without platelets (106/L) were
exposed to ﬂuid shear stress (16 dyne/cm2 for 5 minutes) and analyzed for VWF
cleavage by SDS-PAGE and Western blotting as described in the legend to Figure 1.
Figure 3. Sigmoidal dependence of VWF cleavage on platelet count. Reactions
containing VWF (30 g/mL), without () or with () ADAMTS13 (2.5 U/mL), and
various concentrations of platelets were exposed to ﬂuid shear stress (50 dyne/cm2,
3 minutes) and analyzed by SDS-PAGE and Western blotting. (A) Examples of
platelet dose response results with formalin-ﬁxed platelets (top) and fresh washed
platelets (bottom). (B) Data with ﬁxed platelets were combined by normalizing the
density of the 350-kDa product band to the density of a cleavage product standard
(Std). Error bars indicate SE (n  9).
Figure 4. Platelets increase the cleavage of large VWF multimers under ﬂuid
shear stress. Reactions containing VWF (30 g/mL) were performed as indicated
with () or without ()ADAMTS13 (2.5 U/mL), platelets (2  106/L), and ﬂuid shear
stress (16 dyne/cm2, 10 minutes). The distribution of VWF multimers was assessed
by 1.5% SDS-agarose gel electrophoresis.
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250 000 Da/subunit, 40 nM A1 domains) and platelets
(250 000 platelets/L, 28 000 GPIb/platelet,26 12 nM
GPIb), only aproximately 0.3% ofVWF subunits will be bound to
a platelet. Such low occupancy is consistent with the common
observation that VWF-platelet binding is usually undetectable in
blood under static conditions. This small amount of platelet
binding slightly increases the cleavage of VWF by ADAMTS13
(Figures 1A and 2), probably by increasing the accessibility of
VWF domain A2.12 A variant of GPIb that binds VWF more
tightly causes a correspondingly larger increase in the cleavage of
VWF (Figure 1C).
By itself, shear stress also does not account for the cleavage of
VWF by ADAMTS13 in vivo, because physiologic levels of ﬂuid
shear stress can exert little force on VWF in solution. For example,
at 20 dyne/cm2, a shear stress characteristic of the microvascula-
ture, the peak forces on ﬂuid phase VWF are in the range of 0.2 to
0.8 pN.32 These values are less than the force needed to break a
typical hydrogen bond, which suggests that ﬂuid shear stress
should have a very small effect on the tertiary structure of VWF.
Nevertheless, weak forces in this range are sufﬁcient to cause large
scale changes in the conformation of VWF multimers.33 Under
static conditions, VWF multimers adopt a collapsed, globular
conformation that appears to depend on weak interactions among
the subunits. Above a threshold shear force, the multimer unfurls
and extends reversibly to expose binding sites for collagen and
platelets33 and also to increase the accessibility of VWF domainA2
to ADAMTS13. These considerations are consistent with the
modest increase in VWF cleavage byADAMTS13 as a function of
increasing ﬂuid shear stress, even in the absence of platelets
(Figure 2).
Although each alone has a relatively small effect, the combina-
tionofshearstressandplateletsdramaticallyincreasesthecleavage
of VWF (Figure 2), and this synergism can be explained by the
effect of platelets on the force experienced by VWF. Binding to the
surface of a single platelet should not signiﬁcantly increase the
tension onVWF,32 but the peak force on 2 platelets held together by
VWF is predicted to exceed 390 pN at a shear stress of
20 dyne/cm2.32 This force is enough to unfold many structural
proteins and probably unfolds VWF domain A2, facilitating the
cleavage of its Tyr1605-Met1606 bond byADAMTS13.
The dependence of VWF cleavage on shear stress exhibits a
maximum between 10 and 30 dyne/cm2 (Figure 2A), and the
decline at higher shear stress may have several explanations.
Increasing shear rate will increase the frequency of platelet-VWF
collisions, which should increase the rate of cleavage as well.
However, this effect will be limited because increased shear stress
applies more force to the VWF-GPIb bond, which will accelerate
dissociation from the platelet surface34 and reduce the time during
which a VWF multimer is stretched and exposed for cleavage by
ADAMTS13. Alternatively, ADAMTS13 may prefer a partially
unfolded substrate, and the application of increasing force may
overextend the VWF A2 domain so that ADAMTS13 cannot
recognize it efﬁciently. This mechanism would be consistent with
the ﬁnding that pretreatment with 1.25 mol/L guanidine-HCl
increases the susceptibility of VWF to ADAMTS13, but a higher
concentration causes VWF to become resistant.9,15
A requirement to bind 2 platelets per multimer implies that
cleavage byADAMTS13 should increase exponentially rather than
linearly with platelet count (Figure 6), and it does (Figure 3).
Shear-dependent binding of VWF to platelets35 and shear-induced
platelet aggregation36 also show a similar nonlinear dependence on
Figure 5. Shear stress induces large VWF multimers to bind platelets. Reactions
were performed as indicated with () or without () VWF (30 g/mL), formalin-ﬁxed
platelets (106/L), and ﬂuid shear stress (16 dyne/cm2, 10 minutes). Samples were
diluted with an equal volume of reaction buffer and centrifuged for 5 minutes at
6400g. The platelet pellets (or any other pelleted material for reactions without
platelets) were washed 3 times by resuspension in reaction buffer and centrifugation.
The washed platelets or other contents were dispersed in Laemmli sample buffer,
heated at 80°C for 5 minutes, and centrifuged, and supernatant corresponding to
20 L of the initial reaction volume was analyzed by Western blotting after 1.5%
SDS-agarose gel electrophoresis. The 20 ng of input VWF analyzed for reference
corresponds to approximately 3% of the VWF initially present in the samples of
reactions analyzed in lanes 1 to 4.
Figure 6. Binding of platelets to VWF modeled as a function of platelet count
and multimer length. The fractional occupancy of platelet binding sites on VWF
multimers was calculated from the Kd for platelet GPIb-A1 domain binding
(4 mol/L),25-27 plasma VWF concentration (10 g/mL), VWF subunit mass
(250 kDa), and number of GPIb per platelet (28 000).26 The probability that a
multimer has bound a particular number x of platelets is given by the binomial formula
for P(x,n), where n is the number of VWFA1 domains (or subunits) per multimer and y
is the fractional occupancy of VWF domain A1 sites by GPIb ([GPIb-A1]/[A1]total):
P(0,n)  (1  y)n and P(1,n)  ny(1  y)n1. Therefore, the probability of having at
least 1 platelet bound per multimer is 1  (1  y)n, and the probability of ﬁnding at
least 2 platelets bound per multimer is 1  {(1  y)n  ny(1  y)n1}. At a ﬁxed
multimer length (n  20 subunits), P is greater than or equal to 2 platelets/multimer
increases exponentially with increasing platelet count (A), whereas P is greater than
or equal to 1 platelet/multimer increases approximately linearly with increasing
platelet count (B).At a ﬁxed platelet count (250 000/L), P is greater than or equal to
2 platelets/multimer increases exponentially with increasing multimer length (C),
whereas P is greater than or equal to 1 platelet/multimer increases approximately
linearly with increasing multimer length (D).
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platelets to interact with a single VWF multimer.35
The probability that at least 2 platelets will bind to a multimer is
also expected to increase exponentially with multimer length
(Figure 6). This prediction is consistent with the ﬁnding that
shear-induced, platelet dependent cleavage of VWF consumes
large multimers (Figure 4) and that shear-induced binding of VWF
to platelets preferentially removes the largest multimers (Figure 5).
An exponential relationship between multimer length and cleavage
by ADAMTS13 can account for the selective proteolysis of large
VWF multimers associated with thrombocytosis37,38 or with in-
creased shear stress caused by aortic stenosis.39 Conversely, small
multimers are unlikely to bind 2 platelets and therefore rarely
become stretched enough to present a susceptible cleavage site for
ADAMTS13. Therefore, this relationship also can explain the
striking lack of VWF proteolysis associated with von Willebrand
disease variants in which only small multimers are secreted.40
Platelets and ﬂuid shear stress cooperate to promote VWF
cleavage at several stages in the life history of a VWF multimer.
Immediately after secretion, some ULVWF forms long strings that
bind to the endothelial cell surface.13 In ﬂowing blood, platelets
bind and transmit force to the cell-associated ULVWF strings,
which results in prompt cleavage by ADAMTS13 and release of
VWF into the circulation.14 A similar mechanism prevents the
microvascularthrombosisthatcharacterizesthromboticthrombocy-
topenic purpura. However, substantial proteolysis of VWF multim-
ers also occurs in the ﬂuid phase of circulating blood. For example,
administration of DDAVP induces an acute 3-fold increase in
plasma VWF level that includes a substantial amount of ULVWF.
The ULVWF multimers disappear within 2 to 4 hours, accompa-
nied by increased VWF subunit proteolysis. In contrast, the plasma
concentration of VWF returns to baseline over a longer time course
of 24 hours.41 The rapid evolution of VWF multimers after
DDAVP, with disappearance of “ultralarge” species over 2 to
4 hours, indicates that the shear-induced cleavage of VWF in
solution is a major pathway for the catabolism of VWF in vivo.
This process is sensitive to changes in platelet count, to the size
distribution of VWF multimers, and to normal or pathologic
variations in ﬂuid shear stress.
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